Mesenchymal stem cells enhance lung cancer initiation through activation of IL-6/JAK2/STAT3 pathway

Lung Cancer

Volumn 75, Issue 2, 2012, Pages 167-177

  Hsu, Han Shui ^a,b   Lin, Jiun Han ^a   Hsu, Tien Wei ^a   Su, Kelly ^a   Wang, Cheng Wien ^c   Yang, Kuang Yao ^b   Chiou, Shih Hwa ^a,b   Hung, Shih Chieh ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c Ton Yen General Hospital   (Taiwan)

Author keywords

IL6; JAK2; Lung cancer; Mesenchymal stem cell; STAT3; Tumor initiation

Indexed keywords

INTERLEUKIN 6; JANUS KINASE 2; STAT3 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; LUNG CANCER; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; SCID MOUSE; TUMOR GROWTH;

ANIMALS; CELL LINE, TUMOR; HUMANS; INTERLEUKIN-6; JANUS KINASE 2; LUNG NEOPLASMS; MESENCHYMAL STEM CELLS; MICE; NEOPLASM TRANSPLANTATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANSPLANTATION, HETEROLOGOUS;

EID: 84855472067     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.07.001     Document Type: Article

References (38)

1. Tlsty T.D. Stromal cells can contribute oncogenic signals. Semin Cancer Biol 2001, 11:97-104.
2. Elenbaas B., Weinberg R.A. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res 2001, 264:169-184.
3. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat Rev 2006, 6:392-401.
4. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
5. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557-565.
6. Guest I., Ilic Z., Ma J., Grant D., Glinsky G., Sell S. Direct and indirect contribution of bone marrow-derived cells to cancer. Int J Cancer 2009, 126:2308-2318.
7. Molloy A.P., Martin F.T., Dwyer R.M., Griffin T.P., Murphy M., Barry F.P., et al. Mesenchymal stem cell secretion of chemokines during differentiation into osteoblasts, and their potential role in mediating interactions with breast cancer cells. Int J Cancer 2009, 124:326-332.
8. Lazennec G., Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 2010, 16:133-144.
9. Bergfeld S.A., DeClerck Y.A. Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev 2010, 29:249-261.
10. Kishimoto T. Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 2005, 23:1-21.
11. Schafer Z.T., Brugge J.S. IL-6 involvement in epithelial cancers. J Clin Invest 2007, 117:3660-3663.
12. Hong D.S., Angelo L.S., Kurzrock R. Interleukine-6 and its receptor in cancer. Cancer 2007, 110:1911-1928.
13. Sansone P., Storci G., Tavolari S., Guarnieri T., Giovannini C., Taffurelli M., et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 2007, 117:3988-4002.
14. Bachelot T., Ray-Coguard I., Menetrier-Caux C., Rastkha M., Duc A., Blay J.Y. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J cancer 2003, 88:1721-1726.
15. Knupfer H., Preiss R. Serum interleukin-6 levels in colorectal cancer patients - a summary of published results. Int J Colorectal Dis 2010, 25:135-140.
16. Yeh H.H., Lai W.W., Chen H.H.W., Liu H.S., Su W.C. Autocrine IL-6-induced stats activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene 2006, 25:4300-4309.
17. Gao S.P., Mark K.G., Leslie K., Pao W., Motoi N., Gerald W.L., et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007, 117:3846-3856.
18. Jarnicki A., Putoczki T., Ernst M. Stat3: linking inflammation to epithelial cancer-more than a gut feeling. Cell Div 2010, 5:14.
19. Piekorz R., Schlierf B., Burger R., Hocke G.M. Biochem Biophys Res Commun 1998, 250:436-443.
20. Colomiere M., Ward A.C., Trenerry M.K., Cameron-Smith D., Findlay J., Ackland L., et al. Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer 2009, 100:134-144.
21. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.Y., Vallabhapurapu S., et al. IL-6 and STAT3 are required for survival of intestinal epithelial cells and development of colitis associated cancer. Cancer Cell 2009, 15:103-113.
22. Sekiya I., Larson B.L., Smith J.R., Pochampally R., Cui J.G., Prockop D.J. Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. Stem Cells 2002, 20:530-541.
23. Tsai C.C., Chen Y.J., Yew T.L., Chen L.L., Wang J.Y., Chiu C.H., et al. Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST. Blood 2011, 117:459-469.
24. Hung S.C., Yang D.M., Chang C.F., Lin R.J., Wang J.S., Ho L.L.T., et al. Immortalization without neoplastic transformation of human mesenchymal stem cells by transduction with HPV16 E6/E7 genes. Int J Cancer 2004, 110:313-319.
25. Park S.Y., Kim B.H., Kim J.H., Lee S., Kang G.H. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med 2007, 131:1561-1567.
26. Yang M., Nonaka D. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod Pathol 2010, 23:654-661.
27. Chen Y.C., Hsu H.S., Chen Y.W., Tsai T.H., Hung S.C., Chang Y.L., et al. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS ONE 2008, 3:e2637.
28. Hsu H.-S., Lin J.-H., Huang W.-C., Hsu T.-W., Su K., Chiou S.-H., et al. Chemo-resistance of lung cancer stem-like cells depends on activation of Hsp27. Cancer 2011, 117:1516-1528.
29. Hung S.C., Deng W.P., Yang W.K., Liu R.S., Lee C.C., Su T.C., et al. Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging. Clin Cancer Res 2005, 11:7749-7756.
30. Hall B., Andreeff M., Marini F. The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles. Handb Exp Pharmacol 2007, 180:163-183.
31. Liu C.H., Hwang S.M. Cytokine interactions in mesenchymal stem cells from cord blood. Cytokine 2005, 32:270-279.
32. Coffelt S.B., Marini F.C., Watson K., Zwezdaryk K.J., Dembinski J.L., LaMarca H.L., et al. The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc Natl Acad Sci USA 2009, 106:3806-3811.
33. Spaeth E.L., Dembinski J.L., Sasser A.K. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PloS ONE 2009, 4:e4992.
34. Tlsty T.D., Hein P.W. Know thy neighbors: stromal cells can contribute ondogenic signals. Curr Opin Genet Dev 2001, 11:54-59.
35. Mishra P.J., Mishra P.J., Glod J.W., Banerjee D. Mesenchymal stem cells. Flip side of the coin. Cancer Res 2009, 69:1255-1258.
36. Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R., et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348.
37. Mishra P.J., Mishra P.J., Humeniuk R., Medina D.J., Alexe G., Mesirov J.P., et al. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res 2008, 68:4331-4339.
38. Rattigan Y., Hsu J.M., Mishra P.J., Glod J., Banerjee D. Interleukine 6 mediated recruitment of mesenchymal stem cells to the hypoxic tumor milieu. Exp Cell Res 2010, 316:3417-3424.